Skip to main content
. 2025 Aug 15;17(8):6639–6651. doi: 10.62347/QPXN8103

Table 9.

Comparison of adverse events between the two groups

Parameters Mirena group (n = 81) Mirena combined with Leuprorelin group (n = 63) χ2 P
Vaginal spotting 12 (14.81%) 5 (7.94%) 1.610 0.204
Amenorrhea 16 (19.75%) 15 (23.81%) 0.345 0.557
Breast tenderness 2 (2.47%) 0 (0.00%) 0.290 0.590
Low estrogen 4 (4.94%) 6 (9.52%) 0.553 0.457